Back to Journals » Clinical Ophthalmology » Volume 2 » Issue 4

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration

Total article views   HTML views PDF downloads Totals
5,610 Dovepress* 5,610+ 1,675 7,285
Totals 5,610 1,675 7,285
*Since 5 December 2008
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
1 0 0 0 0 1

View citations on Google Scholar